Cerecor Inc. operates as a biopharmaceutical firm dedicated to the discovery and marketing of therapeutic solutions, primarily addressing rare pediatric and orphan diseases. The company maintains an active pipeline, including: Inherited Metabolic Disorders: Advancing CERC-801 and CERC-802, both of which have successfully completed Phase I clinical trials, alongside CERC-803. Autoimmune Inflammatory Conditions: Developing CERC-007, an anti-IL-18 monoclonal antibody, designed to combat ailments such as adult-onset Still's disease and multiple myeloma. Complex Lymphatic Malformations: Progressing CERC-006, a dual mTOR inhibitor. Pediatric-onset Crohn's Disease: Working on CERC-002, an anti-LIGHT monoclonal antibody. Mitochondrial Disorders: Investigating CERC-913, a protide nucleotide. Rare Auto-inflammatory Diseases: Developing CERC-005, a monoclonal antibody. Symptomatic Orthostatic Hypotension: Pursuing CERC-301. Parkinson's Disease: Researching CERC-406. Beyond its research and development efforts, Cerecor also markets Millipred, an oral prednisolone formulation used to manage various inflammatory ailments. These include conditions affecting the joints (arthritis), blood, immune system, skin, eyes, respiratory system, as well as certain cancers and severe allergies. Established in 2011, when it rebranded from Ceregen Corporation to Cerecor Inc., the company's headquarters are situated in Rockville, Maryland.